The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Lipocalin 2 is essential for chronic kidney disease progression in mice and humans
Open accessAbstract
Mechanisms of progression of chronic kidney disease (CKD), a major health care burden, are poorly understood. EGFR stimulates CKD progression, but the molecular networks that mediate its biological effects remain unknown. We recently showed that the severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Here, we utilized two mouse strains that react differently to nephron reduction--FVB/N mice, which develop severe renal lesions, and B6D2F1 mice, which are resistant to early deterioration--coupled with genome-wide expression to elucidate the molecular nature of CKD progression. Our results showed that lipocalin 2 (Lcn2, also known as neutrophil gelatinase-associated lipocalin [NGAL]), the most highly upregulated gene in the FVB/N strain, was not simply a marker of renal lesions, but an active player in disease progression. In fact, the severity of renal lesions was dramatically reduced in Lcn2-/- mice. We discovered that Lcn2 expression increased upon EGFR activation and that Lcn2 mediated its mitogenic effect during renal deterioration. EGFR inhibition prevented Lcn2 upregulation and lesion development in mice expressing a dominant negative EGFR isoform, and hypoxia-inducible factor 1α (Hif-1α) was crucially required for EGFR-induced Lcn2 overexpression. Consistent with this, cell proliferation was dramatically reduced in Lcn2-/- mice. These data are relevant to human CKD, as we found that LCN2 was increased particularly in patients who rapidly progressed to end-stage renal failure. Together our results uncover what we believe to be a novel function for Lcn2 and a critical pathway leading to progressive renal failure and cystogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron
Flo, T. H., Smith, K. D., Sato, S., Rodriguez, D. J., Holmes, M. A., Strong, R. K., Akira, S., & Aderem, A. (2004) · Nature · doi:10.1038/nature03104 · Cited by 1,877
Goetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E., Raymond, K. N., & Strong, R. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00708-6 · Cited by 1,355
Chronic kidney disease: the global challenge
El Nahas, A. M., & Bello, A. K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17789-7 · Cited by 1,195
Mori, K., Lee, H. T., Rapoport, D., Drexler, I. R., Foster, K., Yang, J., Schmidt-Ott, K. M., Chen, X., Li, J. Y., Weiss, S., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23056 · Cited by 954
Self-citationDual Action of Neutrophil Gelatinase–Associated Lipocalin
Schmidt-Ott, K. M., Mori, K., Li, J. Y., Kalandadze, A., Cohen, D. J., Devarajan, P., & Barasch, J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080882 · Cited by 772
Self-citationA Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake
Devireddy, L. R., Gazin, C., Zhu, X., & Green, M. R. (2005) · Cell · doi:10.1016/j.cell.2005.10.027 · Cited by 672
An Iron Delivery Pathway Mediated by a Lipocalin
Yang, J., Goetz, D., Li, J.-Y., Wang, W., Mori, K., Setlik, D., Du, T., Erdjument-Bromage, H., Tempst, P., Strong, R., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00710-4 · Cited by 651
Self-citationMechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
Remuzzi, G. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27699 · Cited by 618
Cited by
Villanueva, E., Yalavarthi, S., Berthier, C. C., Hodgin, J. B., Khandpur, R., Lin, A. M., Rubin, C. J., Zhao, W., Olsen, S. H., Klinker, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100450 · Cited by 1,241
Chakraborty, S., Kaur, S., Guha, S., & Batra, S. K. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.008 · Cited by 503
Cellular and molecular mechanisms of kidney fibrosis
Djudjaj, S., & Boor, P. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.002 · Cited by 475
Biomarkers in chronic kidney disease: a review
Fassett, R. G., Venuthurupalli, S. K., Gobe, G. C., Coombes, J. S., Cooper, M. A., & Hoy, W. E. (2011) · Kidney International · doi:10.1038/ki.2011.198 · Cited by 449
Lipocalin 2: an emerging player in iron homeostasis and inflammation
Xiao, X., Yeoh, B. S., & Vijay-Kumar, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064559 · Cited by 426
Biomarkers in chronic kidney disease, from kidney function to kidney damage
Lopez-Giacoman, S. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i1.57 · Cited by 392
Reactive astrocytes secrete lcn2 to promote neuron death
Bi, F., Huang, C., Tong, J., Qiu, G., Huang, B., Wu, Q., Li, F., Xu, Z., Bowser, R., Xia, X.-G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218497110 · Cited by 371
Lipocalin-2: Structure, function, distribution and role in metabolic disorders
Jaberi, S. A., Cohen, A., D’Souza, C., Abdulrazzaq, Y. M., Ojha, S., Bastaki, S., & Adeghate, E. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112002 · Cited by 345
Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome
Rysz, J., Gluba-Brzózka, A., Franczyk, B., Jabłonowski, Z., & Ciałkowska-Rysz, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081702 · Cited by 278
Diverse functional roles of lipocalin-2 in the central nervous system
Jha, M. K., Lee, S., Park, D. H., Kook, H., Park, K.-G., Lee, I.-K., & Suk, K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.006 · Cited by 195
Singh, V., Yeoh, B. S., Chassaing, B., Zhang, B., Saha, P., Xiao, X., Awasthi, D., Shashidharamurthy, R., Dikshit, M., Gewirtz, A., et al. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.03.007 · Cited by 117
Bechara, R., Amatya, N., Bailey, R. D., Li, Y., Aggor, F. E. Y., Li, D.-D., Jawale, C. V., Coleman, B. M., Dai, N., Gokhale, N. S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd1287 · Cited by 89
Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
Hwang, S., Yun, H., Moon, S., Cho, Y. E., & Gao, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.751802 · Cited by 84
Song, J., & Kim, O. Y. (2018) · Clinical Nutrition Research · doi:10.7762/cnr.2018.7.1.1 · Cited by 53
“LCN2 was suggested as a sensitive biomarker for various forms of kidney injuries as LCN2 in the renal tubules is highly expressed about 1,000-fold, and released into plasma under infection, or ischemic condition [11-14].”
BackgroundEller, K., Schroll, A., Banas, M., Kirsch, A. H., Huber, J. M., Nairz, M., Skvortsov, S., Weiss, G., Rosenkranz, A. R., & Theurl, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067693 · Cited by 46
Metadata
- Authors
- Viau, A., El Karoui, K., Laouari, D., Burtin, M., Nguyen, C., Mori, K., Pillebout, E., Berger, T., Mak, T. W., Knebelmann, B., Friedlander, G., Barasch, J., & Terzi, F.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-11-01
- Volume
- 120
- Issue
- 11
- Pages
- 4065-4076
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2001370885
- Cited by
- 392
- References
- 49
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.